Latest Articles
Does Canada pay its fair share of the global cost of pharmaceutical innovation?
Brett J Skinner, PhD | Founder and CEO, CHPI; Editor-in-Chief, CHPJ | ABSTRACT – The global
The Economic Burden of Seasonal Influenza in Quebec: Updated Estimates and Policy Implications
RESEARCH ARTICLE | Yanick Labrie, MA | Health Economist, Yanick Labrie Consultant Inc. | Citation:
Bulk purchasing for innovative pharmaceuticals – proceed with caution
Neil Palmer | W.N. Palmer and Co., Ottawa. | DEC 2025 – COMMENT – Citation:
More Articles
-
Does Canada pay its fair share of the global cost of pharmaceutical innovation?
Read more -
The Economic Burden of Seasonal Influenza in Quebec: Updated Estimates and Policy Implications
Read more -
Bulk purchasing for innovative pharmaceuticals – proceed with caution
Read more -
Net direct expenditure on patented medicines by public drug plans in 10 Canadian provinces in 2023
Read more -
Documenting Long-Acting Reversible Contraceptive (LARC) Coverage Across Canada
Read more -
Judicial perspectives on the use of class action litigation as a tool for health policy change
Read more -
Access to new drugs on public formularies in 10 Canadian provinces 2019 to 2024
Read more -
The impact of pharmaceutical innovation on mortality and hospital utilization in Canada, 2000–2022
Read more -
Lessons from Abroad for Canada’s National Dementia Strategy: Actions for Implementation
Read more -
Insights and Opportunities into the State of Precision Oncology in Atlantic Canada Report
Read more -
Better Canadian Health Care Access and Outcomes Requires Moving Toward a Combined Salaried Public and Selected Private Physician Remuneration Model
Read more -
State importation programs are unrealistic: diverting prescription drugs to American consumers would rapidly deplete the Canadian drug supply
Read more -
Les programmes d’importation des États-Unis sont irréalistes : détourner les médicaments d’ordonnance vers les consommateurs américains épuiserait rapidement l’approvisionnement en médicaments au Canada
Read more -
Government development of ‘made-in-Canada’ CAR-T cell immunotherapies: assessing cost, risk, access, and alternatives
Read more -
Identifying Spasticity Treatment Gaps in Long-term Care and Community Settings from Ontario Real-world Evidence
Read more -
Community Trust and Public Health Compliance: COVID-19 Experiences in Newfoundland and Labrador
Read more -
Benefit of expedited regulatory approval for oncology drugs eliminated by slow reimbursement reviews and price negotiations
Read more -
Exploring the Ethics of Paediatric Surgical Prioritization in Canada: A Survey of Existing Institutional Guidance
Read more -
Effects of the COVID-19 pandemic on the number and characteristics of public drug program beneficiaries in Ontario, Canada
Read more -
A Growing Problem: Is Canada’s Healthcare System Keeping Up with Newcomers?
Read more -
A Canadian Healthcare Policy Framework for Clinical Care at the End and the Beginning of Life: Prioritization, Human Resource Management, and Remuneration Models
Read more -
Public v private insurance coverage for new drugs in Canada, 2018-2023, 7th Edition
Read more -
Waiting for new medicines in Canada, Europe, and the United States 2018-2023
Read more -
Patented Medicines Expenditure in Canada 1990–2022 8TH Edition
Read more -
Alberta’s research priorities to advance organ donation and transplantation: an ecosystem-based and consensus-driven approach to strategic research planning.
Read more -
Physician Pay Inequity: Time to Act?
$0.00 Add to cart -
Canadian public payer best practices for providing timely patient access to cancer therapies
$0.00 Add to cart -
Adapting the Safe Consumption Site Model for Patient-Procured MDMA
$0.00 Add to cart -
The Supply of Primary Care Physicians in Alberta 2018-2022 – A Dire Description
$0.00 Add to cart -
Toward a Policy Framework to Improve the Health Care of Homeless Individuals
$0.00 Add to cart -
Evaluation of the PMPRB regulatory performance on price review for new patented drugs in Canada, 2008-2021
$0.00 Add to cart -
Herceptin® treatments in hospital and at CLSCs for breast cancer patients in Quebec: comparative analysis of costs and care trajectories.
$0.00 Add to cart -
Traitements d’Herceptin© à l’hôpital et en CLSC pour les patientes atteintes de cancer du sein au Québec: analyse comparative des coûts et des trajectoires de soins.
$0.00 Add to cart -
New cancer drugs in Canada 2012 to 2021: an economic analysis of cost, benefit, availability, and public insurance coverage.
$0.00 Add to cart -
Economic burden of cardiomyopathy in Canada 2018 to 2021: opportunity for cost avoidance through pharmaceutical innovation.
$0.00 Add to cart -
Policy approaches for increasing participation with personal health information and data sharing (HIDS)
$0.00 Add to cart -
An Evaluation of Access and Policy Initiatives for Breast Cancer Screening in Ontario
$0.00 Add to cart -
Toward a Policy Framework for Sustainable Rural Obstetrics and Surgical Care in Canada
$0.00 Add to cart -
Canada falls behind in new drug submissions compared with the United States and Europe
$0.00 Add to cart -
QALYs and Value Assessment
$0.00 Add to cart -
Healthcare’s search for “wellness”: How bioethics reduces burnout among health professionals
$0.00 Add to cart -
Projected Ontario budget savings from reduced long-term care utilization due to a disease-modifying Alzheimer’s treatment
$0.00 Add to cart -
Integration within Long-Term Care: A Comparative Analysis of Nova Scotia and British Columbia
$0.00 Add to cart -
Effect of amended Patented Medicine Regulations on industry decisions to launch new drugs in Canada
$0.00 Add to cart -
Opportunities to improve health care processes and services outcomes in Canada
$0.00 Add to cart -
Patented Medicines Expenditure in Canada 1990–2020 7th Edition
$0.00 Add to cart -
Patent term erosion and the availability of new medicines in Canada 2000-2022
$0.00 Add to cart -
Liability issues for the use of artificial intelligence (AI) in health care as a home assistance tool
$0.00 Add to cart -
Waiting for new medicines in Canada, Europe and the United States 2016-2021
$0.00 Add to cart -
Access to new medicines in Canada 2016-2021: Federal-provincial public drug programs and private sector drug plans
$0.00 Add to cart -
The PMPRB: Where Are We Now and What’s Next?
$0.00 Add to cart -
Bringing value to healthcare through ambulatory services
$0.00 Add to cart -
Analysis of interventions addressing the nutrition status of seniors in Ontario
$0.00 Add to cart -
A Dollar a Day May Keep the Doctor Away: Putting Spending on Food and Healthcare on a Scale
$0.00 Add to cart -
Pharmacy scope of practice and access to Opioid Agonist Therapies (OAT) in Canada after COVID-19
$0.00 Add to cart -
Champ d’exercice de la pharmacie et accès aux traitements par agonistes opioïdes (TAO) au Canada après la COVID-19
$0.00 Add to cart -
Why would Canada have the longest wait times for an Alzheimer’s treatment among the G7 countries?
$0.00 Add to cart -
Rogue Regulator: PMPRB’s false narrative is driving dangerous drug price controls
$0.00 Add to cart -
Availability and Accessibility of Essential Drugs for Rare Disorders in Canada
$0.00 Add to cart -
Canada’s COVID-19 Vaccine Procurement Strategy: Comparisons with the United Kingdom and Israel
$0.00 Add to cart -
Prix des médicaments brevetés au Canada et dans 13 autres pays
$0.00 Add to cart -
Prices for Patented Medicines in Canada and 13 Other Countries
$0.00 Add to cart -
Home-Based Management of Chronic Diseases
$0.00 Add to cart -
Community Characteristics and MAiD Uptake in Ontario
$0.00 Add to cart -
Oversight of Medical Assistance in Dying (MAiD) in Canada
$0.00 Add to cart -
A Novel Emergency Operating Room Scheduling Software Promotes Efficiency and Cost-Effectiveness
$0.00 Add to cart -
Development of the Patient and Public Involvement Questionnaire for Canadian Formulary Committees
$0.00 Add to cart -
Death Denied or Death Delayed? Outcomes among Nova Scotia patients deemed ineligible for MAiD
$0.00 Add to cart -
Harassment Reporting Mechanisms for Physicians and Medical Trainees in Alberta
$0.00 Add to cart -
Advance Requests for MAiD in Dementia: Survey of Canadian Public and MAiD Practitioners
$0.00 Add to cart -
Patented Medicines Expenditure in Canada 1990-2019
$0.00 Add to cart -
Modernizing Canadian Pharmacists’ Scope of Practice for Controlled Drugs and Substances
$0.00 Add to cart -
Essais cliniques au Canada: signes inquiétants persistent malgré la réponse superficielle du CEPMB
$0.00 Add to cart -
Clinical Trials in Canada: Worrying Signs Remain Despite PMPRB’s Superficial Response
$0.00 Add to cart -
National Strategy for Drugs for Rare Diseases should Prioritize Patients not Cost Containment
$0.00 Add to cart -
Health Technology Assessment Standards and Practices: How Does Canada Compare with Other Countries?
$0.00 Add to cart -
Clinical Trials in Canada: Worrying Signs that PMPRB Changes will Impact Research Investment
$0.00 Add to cart -
Essais cliniques au Canada: des signes inquiétants que l’incertitude liée aux changements du CEPMB affectera les investissements en recherche
$0.00 Add to cart -
Patented Medicines Expenditure in Canada 1990-2018
$0.00 Add to cart -
Canada’s Vaccine Development Capacity and the Federal Government’s Management of COVID-19
$0.00 Add to cart -
E-Mental Health Services and Unmet Needs of Canadians
$0.00 Add to cart -
Universal public funding for dental care in Canada: problems, policies, and politics.
$0.00 Add to cart -
Ensuring early access to a COVID-19 vaccine in Canada
$0.00 Add to cart -
Vaccines policy in Canada: International and Domestic Comparisons.
$0.00 Add to cart -
Career Options and Professional Integration of Internationally Trained Physicians in Canada.
$0.00 Add to cart -
Evidence that regulating pharmaceutical prices negatively affects R&D and access to new medicines.
$0.00 Add to cart -
COVID-19 Economic Costs and the Implicit Value of a Life-Year in Canada
$0.00 Add to cart -
Did the PMPRB censor CHPI’s Submission to its Draft Guidelines Consultation?
$0.00 Add to cart -
Clinical Trials in Canada Decrease: A Sign of Uncertainty Regarding Changes to the PMPRB?
$0.00 Add to cart -
A Socio-Psychological Perspective on Flattening the COVID-19 Curve.
$0.00 Add to cart -
Patented Medicines Costs of Private Insurers: PMPRB Implications.
$0.00 Add to cart -
Fewer new drug approvals in Canada: early indication of unintended consequences from new PMPRB regs?
$0.00 Add to cart -
New Patented Medicine Regulations in Canada: Updated Case Study. (EN/FR)
$0.00 Add to cart -
Nouvelle réglementation sur les médicaments brevetés au Canada: Étude de cas mise à jour.
$0.00 Add to cart -
New drug submissions in the United States and Canada 2014-2019: trends and policy implications.
$0.00 Add to cart -
The costs of Immunoglobulin treatment in hospital and in the home in Quebec
$0.00 Add to cart -
New pathways for U.S. importation threaten Canadian prescription drug supply
$0.00 Add to cart -
Preventive care of the future? Economic analysis of cardiovascular risk management.
$0.00 Add to cart -
Coverage of new medicines in Federal-Provincial public drug plans in Canada 2009-2018
$0.00 Add to cart -
Coverage of new medicines in private versus public drug plans in Canada 2009-2018
$0.00 Add to cart -
Potential impact of U.S. demand on the Canadian supply of 46 prescription drugs.
$0.00 Add to cart -
Clinical Duty to Recontact in Genetic Testing: Insights from the Safety-Related Duty to Recall
$0.00 Add to cart -
Patented drug prices and clinical trials in 31 OECD countries 2017: implications for Canada’s PMPRB.
$0.00 Add to cart -
HTA and public coverage of new mental health drugs in Quebec and Canada.
$0.00 Add to cart -
Medical resources and spending across provincial healthcare systems in Canada.
$0.00 Add to cart -
Medical Resources in Canada and OECD countries. 2019 Edition.000
$0.00 Add to cart -
Close the Gaps: Patient Benefits and Taxpayer Costs of 3 Pharmacare Options
$0.00 Add to cart -
Evidence that innovative medicines improve health and economic outcomes: focused literature review.
$0.00 Add to cart -
Pan-Canadian Pharmaceutical Alliance negotiations 2014-2018
$0.00 Add to cart -
Out-of-pocket prescription drug costs: What are the implications for National Pharmacare?
$0.00 Add to cart -
Taxpayer Cost of National Pharmacare: Disputing the Parliamentary Budget Officer’s Estimate
$0.00 Add to cart -
Coverage of new medicines in Federal-Provincial public drug plans in Canada 2008-2017
$0.00 Add to cart -
Coverage of new medicines in public versus private drug plans in Canada 2008-2017
$0.00 Add to cart -
New Patented Medicine Regulations in Canada: Case Study of a Manufacturer’s Decision-Making
$0.00 Add to cart -
Prescription drug plan coverage 2016: how many Canadians were insured, under-insured or uninsured?
$0.00 Add to cart -
Comparing expert representation on HTA advisory committees in Canada, the UK and Australia
$0.00 Add to cart -
Facts about the cost of patented drugs in Canada: 2018 Edition.
$0.00 Add to cart -
Consequences of over-regulating the prices of new drugs in Canada
$0.00 Add to cart -
Medical devices spending in Canada 2013-2017
$0.00 Add to cart -
Does Canada need a Patented Medicine Prices Review Board?
$0.00 Add to cart -
Societal cost savings from abuse deterrent formulations for prescription opioids in Canada
$0.00 Add to cart -
HTA decisions and access to mental health treatments in Canada’s public drug plans
$0.00 Add to cart -
The fiscal burden of provincial government health spending across Canada
$0.00 Add to cart -
Hospital spending across Canada’s Provinces, 1990-2014
$0.00 Add to cart -
Costs without benefits for patients? Non-medical spending in Canada’s public health system
$0.00 Add to cart -
Les gouvernements pourraient économiser 5 milliards de dollars par année
$0.00 Add to cart -
Cost of physicians across Canada: 2016 Report
$0.00 Add to cart -
How long do new patented medicines have market exclusivity in Canada’s public drug plans?
$0.00 Add to cart -
Governments could save $5 billion annually by allowing user charges for physician services in Canada
$0.00 Add to cart -
Economic evaluations in health technology assessments: what more can be done?
$0.00 Add to cart -
Pan-Canadian Pharmaceutical Alliance: another hurdle for Canadian patients to access new drugs?
$0.00 Add to cart -
Spending on patented drugs in Canada 1990 to 2014.
$0.00 Add to cart -
Coverage for new medicines in public versus private drug plans in Canada.
$0.00 Add to cart -
Fewer treatment options for patients if Canada adopts New Zealand’s prescription drug policies.
$0.00 Add to cart -
Economic cost of delayed access to 14 new cancer medicines in Canada’s public drug plans.
$0.00 Add to cart -
Including off-label drug indications in HTA jeopardizes patient health and discourages innovation
$0.00 Add to cart -
Medical Resource Availability in Canada and 34 OECD countries: 2016 Annual Report
$0.00 Add to cart -
Medical devices and health care costs in Canada and 74 other countries, 2010 to 2015
$0.00 Add to cart -
Medical Resource Availability in Canada’s Provinces: 2016 Annual Report
$0.00 Add to cart -
Pharmacare: what are the costs for patients and taxpayers?
$0.00 Add to cart -
Are cost-effectiveness rules in public drug plans denying coverage to Canadians with rare disorders?
$0.00 Add to cart -
Impact of improved data protection on health costs in Canada and Japan: lessons for the TPP.
$0.00 Add to cart -
Medical devices and health care costs in Canada and 71 other countries. 2015 Annual Report.
$0.00 Add to cart -
Economic value of the utility-expansion for new cancer drugs approved in Canada from 2004 to 2014.
$0.00 Add to cart -
Pharma Funding for Patient Advocacy: Unethical or a Necessity?
$0.00 Add to cart -
Coverage for new medicines in Canada’s public drug plans, 2015.
$0.00 Add to cart -
Challenging drug safety alarmism with facts.
$0.00 Add to cart -
Private versus public drug coverage in Canada. 2014 Annual Report.
$0.00 Add to cart -
Private health insurance costs in Canada.
$0.00 Add to cart -
Canada’s lagging healthcare productivity: Lost efficiencies and missed economic opportunities.
$0.00 Add to cart -
Comparing access to new drugs in Canada’s public drug plans. 2014 Annual Report.
$0.00 Add to cart -
Medical devices and healthcare costs in Canada and 66 other countries. 2014 Annual Report.
$0.00 Add to cart -
Do faster drug approvals increase safety risks? Evidence from Canada and Europe 2003-2012.
$0.00 Add to cart -
Spending on Patented Drugs in Canada. 2014 Annual Report.
$0.00 Add to cart -
Private insurance spending on drugs, dental and vision care in Canada, 1990 to 2010.
$0.00 Add to cart -
Spending on patented drugs in Canada. 2013 Annual Report.
$0.00 Add to cart -
Comparing access to new medicines by therapeutic class in public and private sector plans in Canada.
$0.00 Add to cart -
Comparing access to new drugs in Canada’s public and private sector drug plans. 2013 Annual Report.
$0.00 Add to cart -
Medical devices and healthcare costs in Canada and 65 other countries 2006-2011.
$0.00 Add to cart -
Les coûts potentiels découlant de la substitution thérapeutique des médicaments au Québec.
$0.00 Add to cart -
Potential costs from therapeutic substitution of proton pump inhibitor (PPI) drugs in Quebec.
$0.00 Add to cart -
Adverse drug reactions in Canada: facts v. urban myths.
$0.00 Add to cart -
No link between faster drug approvals, regulatory safety warnings, drug withdrawals in Canada & USA.
$0.00 Add to cart -
Drugs and the public cost of healthcare in Canada.
$0.00 Add to cart -
Complexity and costs of assessing real-world effectiveness of new drugs.
$0.00 Add to cart -
Net societal economic impact in Canada from withholding regulatory approval for generic OxyContin®
Read more
information and ideas for better healthcare
ISSN 2562-9492